Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.

Marta Diaz del Castillo; Søren H Christiansen; Camilla Appel; Sarah Falk; David Paul Drucker Woldbye; Anne-Marie Heegaard

doi:10.1016/j.neuroscience.2018.05.025

Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.

Marta Diaz del Castillo, Søren H Christiansen, Camilla Appel, Sarah Falk, David Paul Drucker Woldbye, Anne-Marie Heegaard

Neuropharm and Genetics

8 Citationer (Scopus)

Abstract

Pain remains a major concern in patients suffering from metastatic cancer to the bone and more knowledge of the condition, as well as novel treatment avenues, are called for. Neuropeptide Y (NPY) is a highly conserved peptide that appears to play a central role in nociceptive signaling in inflammatory and neuropathic pain. However, little is known about the peptide in cancer-induced bone pain. Here, we evaluate the role of spinal NPY in the MRMT-1 rat model of cancer-induced bone pain. Our studies revealed an up-regulation of NPY-immunoreactivity in the dorsal horn of cancer-bearing rats 17 days after inoculation, which could be a compensatory antinociceptive response. Consistent with this interpretation, intrathecal administration of NPY to rats with cancer-induced bone pain caused a reduction in nociceptive behaviors that lasted up to 150 min. This effect was diminished by both Y1 (BIBO3304) and Y2 (BIIE0246) receptor antagonists, indicating that both receptors participate in mediating the antinociceptive effect of NPY. Y1 and Y2 receptor binding in the spinal cord was unchanged in the cancer state as compared to sham-operated rats, consistent with the notion that increased NPY results in a net antinociceptive effect in the MRMT-1 model. In conclusion, the data indicate that NPY is involved in the spinal nociceptive signaling of cancer-induced bone pain and could be a new therapeutic target for patients with this condition.

Originalsprog	Engelsk
Tidsskrift	Neuroscience
Vol/bind	384
Sider (fra-til)	111-119
ISSN	0306-4522
DOI	https://doi.org/10.1016/j.neuroscience.2018.05.025
Status	Udgivet - 1 aug. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1016/j.neuroscience.2018.05.025

https://arxiv.org/ftp/arxiv/papers/1809/1809.00895.pdfLicens: CC BY-NC-ND

Citationsformater

@article{f0b7a58277414043a621c90a85602133,

title = "Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.",

abstract = "Pain remains a major concern in patients suffering from metastatic cancer to the bone and more knowledge of the condition, as well as novel treatment avenues, are called for. Neuropeptide Y (NPY) is a highly conserved peptide that appears to play a central role in nociceptive signaling in inflammatory and neuropathic pain. However, little is known about the peptide in cancer-induced bone pain. Here, we evaluate the role of spinal NPY in the MRMT-1 rat model of cancer-induced bone pain. Our studies revealed an up-regulation of NPY-immunoreactivity in the dorsal horn of cancer-bearing rats 17 days after inoculation, which could be a compensatory antinociceptive response. Consistent with this interpretation, intrathecal administration of NPY to rats with cancer-induced bone pain caused a reduction in nociceptive behaviors that lasted up to 150 min. This effect was diminished by both Y1 (BIBO3304) and Y2 (BIIE0246) receptor antagonists, indicating that both receptors participate in mediating the antinociceptive effect of NPY. Y1 and Y2 receptor binding in the spinal cord was unchanged in the cancer state as compared to sham-operated rats, consistent with the notion that increased NPY results in a net antinociceptive effect in the MRMT-1 model. In conclusion, the data indicate that NPY is involved in the spinal nociceptive signaling of cancer-induced bone pain and could be a new therapeutic target for patients with this condition.",

author = "{Diaz del Castillo}, Marta and Christiansen, {S{\o}ren H} and Camilla Appel and Sarah Falk and Woldbye, {David Paul Drucker} and Anne-Marie Heegaard",

year = "2018",

month = aug,

day = "1",

doi = "10.1016/j.neuroscience.2018.05.025",

language = "English",

volume = "384",

pages = "111--119",

journal = "Neuroscience",

issn = "0306-4522",

publisher = "Pergamon Press",

}

TY - JOUR

T1 - Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.

AU - Diaz del Castillo, Marta

AU - Christiansen, Søren H

AU - Appel, Camilla

AU - Falk, Sarah

AU - Woldbye, David Paul Drucker

AU - Heegaard, Anne-Marie

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Pain remains a major concern in patients suffering from metastatic cancer to the bone and more knowledge of the condition, as well as novel treatment avenues, are called for. Neuropeptide Y (NPY) is a highly conserved peptide that appears to play a central role in nociceptive signaling in inflammatory and neuropathic pain. However, little is known about the peptide in cancer-induced bone pain. Here, we evaluate the role of spinal NPY in the MRMT-1 rat model of cancer-induced bone pain. Our studies revealed an up-regulation of NPY-immunoreactivity in the dorsal horn of cancer-bearing rats 17 days after inoculation, which could be a compensatory antinociceptive response. Consistent with this interpretation, intrathecal administration of NPY to rats with cancer-induced bone pain caused a reduction in nociceptive behaviors that lasted up to 150 min. This effect was diminished by both Y1 (BIBO3304) and Y2 (BIIE0246) receptor antagonists, indicating that both receptors participate in mediating the antinociceptive effect of NPY. Y1 and Y2 receptor binding in the spinal cord was unchanged in the cancer state as compared to sham-operated rats, consistent with the notion that increased NPY results in a net antinociceptive effect in the MRMT-1 model. In conclusion, the data indicate that NPY is involved in the spinal nociceptive signaling of cancer-induced bone pain and could be a new therapeutic target for patients with this condition.

AB - Pain remains a major concern in patients suffering from metastatic cancer to the bone and more knowledge of the condition, as well as novel treatment avenues, are called for. Neuropeptide Y (NPY) is a highly conserved peptide that appears to play a central role in nociceptive signaling in inflammatory and neuropathic pain. However, little is known about the peptide in cancer-induced bone pain. Here, we evaluate the role of spinal NPY in the MRMT-1 rat model of cancer-induced bone pain. Our studies revealed an up-regulation of NPY-immunoreactivity in the dorsal horn of cancer-bearing rats 17 days after inoculation, which could be a compensatory antinociceptive response. Consistent with this interpretation, intrathecal administration of NPY to rats with cancer-induced bone pain caused a reduction in nociceptive behaviors that lasted up to 150 min. This effect was diminished by both Y1 (BIBO3304) and Y2 (BIIE0246) receptor antagonists, indicating that both receptors participate in mediating the antinociceptive effect of NPY. Y1 and Y2 receptor binding in the spinal cord was unchanged in the cancer state as compared to sham-operated rats, consistent with the notion that increased NPY results in a net antinociceptive effect in the MRMT-1 model. In conclusion, the data indicate that NPY is involved in the spinal nociceptive signaling of cancer-induced bone pain and could be a new therapeutic target for patients with this condition.

U2 - 10.1016/j.neuroscience.2018.05.025

DO - 10.1016/j.neuroscience.2018.05.025

M3 - Journal article

C2 - 29852245

SN - 0306-4522

VL - 384

SP - 111

EP - 119

JO - Neuroscience

JF - Neuroscience

ER -

Neuropeptide Y is Up-regulated and Induces Antinociception in Cancer-induced Bone Pain.

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater